ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
36 announcements with these filters
Metropolis Healthcare allotted 66,312 equity shares to employees under its RSU Plan, 2020. This exercise follows the vesting of RSUs previously granted to staff.
Metropolis Healthcare's subsidiary MQSPL will issue shares to Medsource and Dr. Puneet Kumar Nigam for ₹1.26 Crore, diluting MHL's stake to 54.90% through this strategic restructuring.
Franklin Templeton Mutual Fund acquired 7,42,409 Metropolis Healthcare shares via open market, raising its stake to 5.10%. No transaction value was disclosed in the filing.
Metropolis Healthcare transferred its External Quality Assessment Services Division to subsidiary MQSPL for ₹1.25 Crore. The transfer was executed via a slump sale.
Metropolis Healthcare's subsidiary, MQSPL, will issue 10,000 Optionally Convertible Redeemable Preference Shares (OCRPS) to Dr. Puneet Kumar Nigam. Post-conversion, MQSPL will remain a subsidiary.
Metropolis Healthcare held its 26th Annual General Meeting on August 18, 2026. Shareholders reviewed financial statements and confirmed previous interim dividend payments.
Duru Shah Family Trust (promoter group) sold 10,50,000 shares of Metropolis Healthcare Ltd via open market on August 11, 2026.
Metropolis Healthcare reports a strong Q1FY27, beating its own revenue guidance through volume-led growth and aggressive tier-2/3 expansion.
Metropolis Healthcare has delayed the slump sale of its EQAS division to a subsidiary. The completion date is now extended to October 4, 2026.
Metropolis Healthcare reports strong Q1FY27 results with Revenue at INR 450 Cr (up 17% YoY) and EBITDA at INR 113 Cr (up 27% YoY).
Metropolis Healthcare reported Q1FY27 revenue of ₹450 crore and PAT of ₹57 crore, reflecting strong operational performance and volume growth.
Metropolis Healthcare Ltd reported revenue from operations of ₹450.2 Cr (+16.6% YoY) and net profit of ₹56.9 Cr (+25.9% YoY) for Q1 FY27.
Metropolis Healthcare Ltd allotted 18,700 equity shares under its Restrictive Stock Unit Plan 2020. The company also granted 21,880 options under various employee stock schemes.
Metropolis Healthcare Ltd. has scheduled a board meeting on August 04, 2026, to consider and approve its unaudited standalone and consolidated financial results.
Metropolis Healthcare Limited has issued the notice for its 26th Annual General Meeting, scheduled for August 18, 2026, to address financial statements and director re-appointments.
Metropolis Healthcare Limited submitted its Business Responsibility and Sustainability Report for the financial year 2025-26, as required by SEBI (LODR) Regulations.
Metropolis Healthcare has released its Annual Report for FY 2025-26, along with the notice for its 26th AGM to be held on August 18, 2026.
Metropolis Healthcare Ltd has filed its quarterly shareholding pattern statement for the period ended June 30, 2026, as per regulatory requirements.
Metropolis Healthcare allotted equity shares under its Restrictive Stock Unit Plan. The issuance expands employee ownership with a marginal increase in share capital.
Metropolis Healthcare increased paid‑up share capital by ₹0.01 Crore through re‑issue of forfeited shares. The capital now stands at approximately ₹41.47 Crore.
Metropolis Healthcare allotted 36,900 equity shares at ₹2 each, amounting to ₹73,800 (≈0.01 Cr) under its 2020 RSU plan. The shares rank pari‑passu with existing equity.
Metropolis reported 16% YoY revenue growth in Q1FY27, driven by patient volumes and product mix. TruHealth and Specialty segments led growth; EBITDA margins improved YoY.
Metropolis Healthcare submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report confirms overall regulatory compliance with no material deviations.
Metropolis Healthcare reports strong FY26 performance with 23.6% YoY revenue growth and 24.4% EBITDA margin. Strategy focuses on network productivity, genomics, and expanding 'mini hubs' for pathology and basic radiology.
Metropolis Healthcare shows strong organic momentum, beating FY26 revenue guidance. Management is shifting focus from aggressive lab expansion to productivity-led growth and margin recovery through operating leverage.
Metropolis Healthcare corrected a reporting error in its historical consolidated profit figures. This administrative update ensures financial transparency without impacting current year results.
Metropolis Healthcare approved Deloitte Haskins & Sells as statutory auditors for a five-year term. President Nilesh Shah transitions to an advisory role, ceasing as Senior Management Personnel.
Metropolis Healthcare reported Q4FY26 revenue of ₹425 Crore, up 23% YoY. Strong growth across B2C and B2B segments drove a 75% rise in profit.
Metropolis Healthcare reports strong FY26 growth, with Group Revenue up 24% and PAT up 31% YoY. The company is executing its 'Metropolis 3.0' strategy focused on specialty tests and network expansion.
Metropolis Healthcare declared an interim dividend of ₹1 per equity share for FY 2025-26. The record date is set for May 19, 2026.